title: Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study.
abstract: Long-term use of calcineurine inhibitors (CNIs) may contribute to the development of chronic allograft dysfunction (CAD). We investigate the impact of the introduction of MMF combined with cyclosporine (CsA) 50% dose reduction. An open, randomized, controlled, multicenter, prospective study was conducted in 103 patients, receiving a CsA-based therapy with a serum creatinine between 1.7-3.4 mg/dL, more than 1 year after transplantation. They were randomized to receive MMF with half dose of CsA (MMF group) or to continue their maintenance CsA dose (control group). A total of 96 weeks after randomization, the evolution of renal function assessed by regression line analysis of 1/SeCr improved in the MMF group (positive slope) vs. the control group (negative slope), 4.2 x 10(-4) vs. -3.0 x 10(-4), respectively (p < 0.001). Concurrently, the absolute renal function improved significantly in the MMF group. No episode of biopsy-proven acute rejection occurred. One patient in each group lost his graft because of biopsy-proven chronic allograft nephropathy. There was a significant decrease of triglycerides level in the MMF group. Anemia and diarrhea were statistically more frequent in the MMF group. In CAD, the reduction of CsA in the presence of MMF results in significant improvement in renal function during a 2-year follow-up.
authors.affiliation: Service de Néphrologie/Transplantation, Nancy-Université, France.
authors.forename: L
authors.initials: L
authors.lastname: Frimat
authors.forename: E
authors.initials: E
authors.lastname: Cassuto-Viguier
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
authors.forename: C
authors.initials: C
authors.lastname: Noël
authors.forename: F
authors.initials: F
authors.lastname: Provôt
authors.forename: L
authors.initials: L
authors.lastname: Rostaing
authors.forename: D
authors.initials: D
authors.lastname: Glotz
authors.forename: J D
authors.initials: JD
authors.lastname: Sraer
authors.forename: B
authors.initials: B
authors.lastname: Bourbigot
authors.forename: B
authors.initials: B
authors.lastname: Moulin
authors.forename: P
authors.initials: P
authors.lastname: Lang
authors.forename: D
authors.initials: D
authors.lastname: Ducloux
authors.forename: C
authors.initials: C
authors.lastname: Pouteil-Noble
authors.forename: S
authors.initials: S
authors.lastname: Girardot-Seguin
authors.forename: M
authors.initials: M
authors.lastname: Kessler
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology / Q000276:immunology; D012449:Safety; D014184:Transplantation, Homologous / Q000276:immunology* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D016572:Cyclosporine; D009173:Mycophenolic Acid